Clinical Trial Update: Pharmacokinetic Interactions of ENG Subdermal Implants with Long-Acting Cabotegravir (CAB-LA) and LA Rilpivirine (RPV-LA) (CARLA) [Phase 4]

View source ↗

Summary

A Phase 4 pharmacokinetic interaction study (CARLA) assessing etonogestrel subdermal implants with long-acting cabotegravir and rilpivirine has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Cabotegravir long-acting (CAB-LA) (cabotegravir)
• Etonogestrel subdermal implant (ENG Subdermal Implant) (etonogestrel)
• Rilpivirine long-acting (RPV-LA) (rilpivirine)

Snippet

Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Conditions: HIV-1-infection | Phase 4 | Status: WITHDRAWN